This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch
by Zacks Equity Research
IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma.
Strategic Acquisitions to Support STERIS Stock Amid Macro Issues
by Zacks Equity Research
STE expects bioprocessing revenues to grow in the second half of fiscal 2025.
Charles River Launches Apollo for CRADL to Boost Research, Stock Rises
by Zacks Equity Research
CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
by Zacks Equity Research
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line?
by Zacks Equity Research
Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
by Zacks Equity Research
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
Should Edwards Lifesciences Stock Stay in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
Illumina Partners NVIDIA for Genomic Advancements, ILMN Stock Climbs
by Zacks Equity Research
ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes
by Zacks Equity Research
With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check.
Macroeconomic Woes, Competition Weigh on TMO's Stock Performance
by Zacks Equity Research
The industry-wide trend of difficult macroeconomic conditions is creating a challenging business environment for Thermo Fisher.
BRKR Stock Up on the Launch of LUMOS II ILIM QCL-Based IR Microscope
by Zacks Equity Research
Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Expanding Global Network, Vaccine Sales Support PAHC Stock
by Zacks Equity Research
Phibro Animal Health is focusing on new developments along with incremental registrations and growing volumes of existing vaccine technologies.
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain?
by Zacks Equity Research
TNDM enters a multi-year research collaboration with the UVA Center for Diabetes Technology for the development of AID systems.
3 Reasons Growth Investors Will Love Phibro (PAHC)
by Zacks Equity Research
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
PAHC or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Exact Sciences Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
EXAS' solid focus on expanding its lead Cologuard test and advancing new solutions bodes well for investors.
ILMN Stock Set to Gain From Latest Updates to the NovaSeq X Series
by Zacks Equity Research
Illumina advances NovaSeq X Series with a software upgrade and the new 25B 100-cycle and 200-cycle kits.
Should National Vision Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about EYE stock, courtesy of its share gain in the Owned and Host segments.
Macroeconomic Woes, FX Headwind Drag NEOG Stock Down
by Zacks Equity Research
NEOG faces intense competition due to the development of new technologies by competitors, which could affect the marketability and profitability of its products.
Reasons to Retain Phibro Stock in Your Portfolio Now
by Zacks Equity Research
PAHC's prospering Vaccine business sparks optimism for future growth. However, headwinds such as unfavorable foreign exchange might hamper the company's operations.
Phibro Animal Health Gains 83% in a Year: What's Driving the Stock?
by Zacks Equity Research
PAHC shares gain owing to the remarkable performance of the Animal Health business and potential in the emerging markets.
Should You Retain Labcorp Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.
Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes
by Zacks Equity Research
Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency.